Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024
DOI: 10.1111/ddg.15403 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2024. Verfasst von Alexandra Strobel und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Epidemiology, Biostatistics, and Informatics, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germa…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Quality of Life. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LENICURA GmbH.
Abstract (Originalsprache)
Background and objectives Hidradenitis suppurativa (HS)/Acne inversa (Ai) is a chronic debilitating disease with limited therapy options. The device‐based LAight therapy was approved in Europe in 2017. The aim of this study was to evaluate the effect of real‐world care with at least one treatment with LAight therapy on disease activity and burden in 3,437 patients. Patients and Methods Patients were included in the analysis if they had a diagnosis of HS and received at least one treatment. The endpoints Hidradenitis Suppurativa Severity Score System (IHS4), pain on the numeric rating scale (pain‐NRS) and Dermatology Life Quality Index (DLQI) were analyzed using a linear mixed model for repeated measures (MMRM) over 26 weeks of care with LAight therapy. Furthermore, responder rates were calculated for all endpoints, and the therapy's safety profile and patient satisfaction were thoroughly examined.
Results
A significant decrease in IHS4, pain‐NRS, and DLQI was achieved during 26 weeks of care with LAight. The BMI at baseline had a significant negative effect on therapy response for pain‐NRS and DLQI.
Conclusions
This study confirms that LAight therapy leads to satisfactory disease control in all stages of severity and is a valuable addition to the therapeutic repertoire of HS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Epidemiology, Biostatistics, and Informatics, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
- Profile Centre of Health Sciences Halle, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
- Dept. of Dermatology, University Medical Center, Johannes Gutenberg, University, Mainz, Germany.
- Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.
- Department of Dermatology, Faculty of Medicine, University of Cologne, Cologne, Germany.
- Dermatology Outpatient Office Dr. Simone Garcovich, Rome, Italy.
ORCID-Profile: Alexandra Strobel, Caroline Mann
Förderung
- LENICURA GmbH
Zitieren
APA
Strobel, A., Schultheis, M., Staubach, P., Grabbe, S., Mann, C., Hennig, K., Szepietowski, J. C., Matusiak, L., Krajewski, P., von Stebut, E., Garcovich, S., Bayer, H., Heise, M., Podda, M., Kirschner, U., & Nikolakis, G. (2024). Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15403
Vancouver
Strobel A, Schultheis M, Staubach P, Grabbe S, Mann C, Hennig K, et al. Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024. doi:10.1111/ddg.15403
BibTeX
@article{Strobel2024,
author = {Strobel, Alexandra and Schultheis, Michael and Staubach, Petra and Grabbe, Stephan and Mann, Caroline and Hennig, Katharina and Szepietowski, Jacek C and Matusiak, Lukasz and Krajewski, Piotr and von Stebut, Esther and Garcovich, Simone and Bayer, Hans and Heise, Marcus and Podda, Maurizio and Kirschner, Uwe and Nikolakis, Georgios},
title = {Real‐world effectiveness and safety of the LAight‐therapy in patients with hidradenitis suppurativa},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2024},
doi = {10.1111/ddg.15403}
}
EUVIMED